Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Merck's (MRK +0.6%) potential blockbuster insomnia drug suvorexant performs well in two-late...

  • Wednesday, June 13, 2012, 11:36 AM ET
    Merck's (MRK +0.6%) potential blockbuster insomnia drug suvorexant performs well in two-late stage trials, helping patients fall asleep faster and stay in dreamland for longer than a placebo. Suvorexant is designed to minimize morning grogginess, although the major side effects were headaches and...tiredness. Still, Merck intends to file for FDA approval this year.
Track new comments on this story

This news story has 1 comment:

  •  
    Waking up from a good night sleep with a headache and tiredness? Can anyone call that a good night sleep? May be it's not a bad idea for the pharma industry. A sleeping pill before bedtime then quickly a heavy dose of aspirin upon rising. Better still, Merck and Bayer should join effort to make a combo of suvorexant and delayed-acting aspirin formulation. Good luck Merck! The jury is still out on this one.

    I personally own Merck stocks and am trying to shed some to decrease liability.
    13 Jun 2012, 11:48 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »